Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O75648

UPID:
MTU1_HUMAN

ALTERNATIVE NAMES:
MTO2 homolog

ALTERNATIVE UPACC:
O75648; A8K3U7; Q05C99; Q5W9C8; Q66K31; Q6ICC3; Q9NWC1

BACKGROUND:
The enzyme Mitochondrial tRNA-specific 2-thiouridylase 1, alternatively known as MTO2 homolog, is pivotal for mitochondrial tRNA modification. It specifically catalyzes the 2-thiolation of uridine, facilitating the formation of 5-taurinomethyl-2-thiouridine in mitochondrial tRNAs. This modification is critical for the accuracy and efficiency of mitochondrial protein synthesis.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in conditions like aminoglycoside-induced deafness and transient infantile liver failure, Mitochondrial tRNA-specific 2-thiouridylase 1 represents a significant target for drug discovery. The elucidation of its role offers promising avenues for the development of novel therapeutic strategies aimed at correcting mitochondrial dysfunctions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.